Account
A federal appeals court Thursday overturned a $593 million patent-infringement award against Johnson & Johnson's (JNJ) Cordis subsidiary, ruling the company didn't infringe a doctor's patent on heart-stent technology.The U.S. Court of Appeals for the Federal Circuit said a Texas federal trial judge misconstrued the claimed inventions in a patent held by Dr. Bruce N. Saffran. Under a correct reading of the patent's claims, Cordis's Cypher stents didn't infringe on the doctor's invention, the court said.Thursday's ruling overturned a 2011 jury verdict in favor of Dr. Saffran that awarded $482 million in patent-infringement damages against Cordis. The judge then added in another $111 million in interest.The doctor had sued several stent makers and obtained a $501 million award in 2008 against Boston Scientific Corp. (BSX). After Boston Scientific appealed the jury verdict in its case, the two sides settled before the appeals court issued a ruling, with the company agreeing to pay about $5...
Bespoke Investment co-founder Paul Hickey on the outlook for the markets.
Gamco Investors Portfolio Manager Jeff Jonas on the investment opportunities in the health-care sector.
It is a big "if" regardless of sector or asset class, the "if" being possible help from Capitol Hill, but it is possible that a group of U.S. senators could boost th...
Analysts at Bernstein Research on Tuesday lowered their rating on Boston Scientific Corp. to market-perform from their earlier rating of outperform, and kept their p...
Hospital stocks surged Wednesday while big health insurers slumped following President Barack Obama's re-election, which solidified the future of a complex health-ca...
Hospital stocks surged while big health insurers slumped following President Barack Obama's re-election, which solidified the future of a complex health-care overhau...
Boston Scientific Corp.'s (BSX) new Chief Executive Michael Mahoney says he will move to cut costs, stanch the flow of executive turnover, and boost research-and-dev...
Some of the world's largest health-care companies, many of them based along the East Coast or with major operations there, closed sites and asked employees to work f...
Corporate America has been talking a good game this earnings season, but a closer look shows the results are not nearly as strong as CEO optimism might lead investor...
Corporate America has been talking a good game this earnings season, but a closer look shows the results are not nearly as strong as CEO optimism might lead investor...
FBN’s Diane Macedo breaks down the stories moving the markets around the world.
Boston Scientific Corp reported a quarterly net loss due to charges and weaker sales on Thursday, but results were better than expected excluding items.The medical d...
A federal appeals court Thursday overturned a $593 million patent-infringement award against Johnson & Johnson's (JNJ) Cordis subsidiary, ruling the company didn't i...
Mending a young person's broken heart may make for a good love story, but can it prevent strokes?That's a question the U.S. Food and Drug Administration is expected ...
Edwards Lifesciences (EW) said a new version of its nonsurgical heart valve met its primary study goal in a late-stage trial, and that it would seek U.S. regulatory ...
Edwards Lifesciences Corp. (EW) said that a new version of its nonsurgical heart valve met its primary study goal in a late-stage trial, and that it would seek U.S. ...
FBN's Nicole Petallides on stocks impacting the afternoon markets.
Boston Scientific Corp reported weaker quarterly earnings on Tuesday as sales slipped and expenses rose, and the medical device maker announced more job cuts.The com...
Boston Scientific (NYSE:BSX) said Tuesday that its board has agreed to expand the company's 2011 restructuring program, which includes cutting another 1,000 jobs thi...
